Research Reports Initiation on Biotech Stocks -- Sarepta Therapeutics, Galena Biopharma, Anthera Pharma, and Clovis Oncology

Friday, April 7, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 7, 2017 /PRNewswire/ -- has initiated coverage on Sarepta Therapeutics Inc. (NASDAQ:

SRPT), Galena Biopharma Inc. (NASDAQ: GALE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Clovis Oncology Inc. (NASDAQ: CLVS). Biotechnology companies are among the most research-intensive organizations in the world. Their product pipelines, a vital
component of expansion, are capital intensive. Learn more about these stocks by downloading their free report at:

Sarepta Therapeutics

On Thursday, shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. recorded a trading volume of 1.39 million shares. The stock ended the session 0.38% higher at $29.32. The Company's shares have 6.89% on an YTD basis. The stock is trading 2.87% below its 50-day moving average. Moreover, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have a Relative Strength Index (RSI) of 46.05.

On April 05th, 2017, Sarepta Therapeutics announced that the Company granted an equity award on April 03rd, 2017, to Dr. Catherine Stehman-Breen. The award was previously approved by the Compensation Committee of the Company's Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to Dr. Stehman-Breen's employment as Chief Medical Officer.

On April 05th, 2017, research firm SunTrust upgraded the Company's stock rating from 'Hold' to 'Buy'. The free research report on SRPT is available at:

Galena Biopharma

San Ramon, California-based Galena Biopharma Inc.'s stock closed the day 1.15% higher at $0.61, with a total trading volume of 467,703 shares. The Company's shares have advanced 1.15% in the past month. The stock is trading 26.99% below their 50-day moving average. Additionally, shares of Galena Biopharma, which develops hematology and oncology therapeutics that address unmet medical needs, have an RSI of 35.08.

On April 04th, 2017, Galena Biopharma announced that a poster was presented on the Company's NeuVax™ (nelipepimut-S) investigator-sponsored Phase-2 clinical trial in high-risk, HER2 3+ patients at the American Association for Cancer Research Annual Meeting 2017 in Washington, DC. The poster presented the interim safety analysis that was initiated after enrollment of the 50th patient in the trial. The complimentary report on GALE can be downloaded at:

Anthera Pharma  

Shares in Hayward, California headquartered Anthera Pharmaceuticals Inc. recorded a trading volume of 2.30 million shares. The stock ended yesterday's trading session 5.73% lower at $0.39. The Company's shares are trading below their 50-day moving average by 31.21%. Furthermore, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have an RSI of 33.78. Visit us today and download our complete research report on ANTH for free at:

Clovis Oncology  

Boulder, Colorado headquartered Clovis Oncology Inc.'s stock finished Thursday's session 4.73% lower at $56.83. A total volume of 2.64 million shares was traded, which was above their three months average volume of 2.18 million shares. The Company's shares have advanced 22.66% over the previous three months and 27.94% since the start of this year. The stock is trading above its 200-day moving average by 48.63%. Additionally, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have an RSI of 37.15. Get free access to your technical report on CLVS at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store